LIVIVO - Search results -

Search results

Result 1 - 10 of total 47

Search options

Article ; Online: With regards to Ellsworth et al. on "Lymphocyte sparing normal tissue effects in the clinic LymphoTEC): A systematic review of dose constraint considerations to mitigate radiation-related lymphopenia in the era of immunotherapy".

Venkatesulu, BhanuPrasad / Giridhar, Prashanth

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

2023 Volume 181, Page(s) 109496

MeSH term(s)	Humans ; Lymphopenia/etiology ; Lymphocytes ; Immunotherapy
Language	English
Publishing date	2023-02-02
Publishing country	Ireland
Document type	Systematic Review ; Letter ; Comment
ZDB-ID	605646-5
ISSN	1879-0887 ; 0167-8140
ISSN (online)	1879-0887
ISSN	0167-8140
DOI	10.1016/j.radonc.2023.109496
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1926: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Radiosensitization by inhibiting DNA repair: Turning the spotlight on homologous recombination.

Venkatesulu, Bhanu P / Krishnan, Sunil

Hepatology (Baltimore, Md.)

2017 Volume 67, Issue 2, Page(s) 470–472

MeSH term(s)	Animals ; Carcinoma, Hepatocellular ; DNA Repair ; Histone Deacetylases ; Homologous Recombination ; Liver Neoplasms ; Mice ; Ubiquitin-Conjugating Enzymes
Chemical Substances	Ubiquitin-Conjugating Enzymes (EC 2.3.2.23) ; Histone Deacetylases (EC 3.5.1.98)
Language	English
Publishing date	2017-12-28
Publishing country	United States
Document type	Editorial ; Comment
ZDB-ID	604603-4
ISSN	1527-3350 ; 0270-9139
ISSN (online)	1527-3350
ISSN	0270-9139
DOI	10.1002/hep.29526
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1660: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Dosimetric and workflow impact of synthetic-MRI use in prostate high-dose-rate brachytherapy.

Podgorsak, Alexander R / Venkatesulu, Bhanu P / Abuhamad, Mohammad / Harkenrider, Matthew M / Solanki, Abhishek A / Roeske, John C / Kang, Hyejoo

Brachytherapy

2023 Volume 22, Issue 5, Page(s) 686–696

Abstract: Purpose: Target and organ delineation during prostate high-dose-rate (HDR) brachytherapy treatment planning can be improved by acquiring both a postimplant CT and MRI. However, this leads to a longer treatment delivery workflow and may introduce ... ...

Abstract	Purpose: Target and organ delineation during prostate high-dose-rate (HDR) brachytherapy treatment planning can be improved by acquiring both a postimplant CT and MRI. However, this leads to a longer treatment delivery workflow and may introduce uncertainties due to anatomical motion between scans. We investigated the dosimetric and workflow impact of MRI synthesized from CT for prostate HDR brachytherapy. Methods and materials: Seventy-eight CT and T2-weighted MRI datasets from patients treated with prostate HDR brachytherapy at our institution were retrospectively collected to train and validate our deep-learning-based image-synthesis method. Synthetic MRI was assessed against real MRI using the dice similarity coefficient (DSC) between prostate contours drawn using both image sets. The DSC between the same observer's synthetic and real MRI prostate contours was compared with the DSC between two different observers' real MRI prostate contours. New treatment plans were generated targeting the synthetic MRI-defined prostate and compared with the clinically delivered plans using target coverage and dose to critical organs. Results: Variability between the same observer's prostate contours from synthetic and real MRI was not significantly different from the variability between different observer's prostate contours on real MRI. Synthetic MRI-planned target coverage was not significantly different from that of the clinically delivered plans. There were no increases above organ institutional dose constraints in the synthetic MRI plans. Conclusions: We developed and validated a method for synthesizing MRI from CT for prostate HDR brachytherapy treatment planning. Synthetic MRI use may lead to a workflow advantage and removal of CT-to-MRI registration uncertainty without loss of information needed for target delineation and treatment planning.
MeSH term(s)	Male ; Humans ; Prostate/diagnostic imaging ; Prostatic Neoplasms/diagnostic imaging ; Prostatic Neoplasms/radiotherapy ; Brachytherapy/methods ; Workflow ; Retrospective Studies ; Radiotherapy Dosage ; Radiotherapy Planning, Computer-Assisted/methods ; Magnetic Resonance Imaging/methods
Language	English
Publishing date	2023-06-12
Publishing country	United States
Document type	Journal Article
ZDB-ID	2098608-7
ISSN	1873-1449 ; 1538-4721
ISSN (online)	1873-1449
ISSN	1538-4721
DOI	10.1016/j.brachy.2023.05.005
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6116: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: CXC chemokine receptor 4 (CXCR4) targeted gold nanoparticles potently enhance radiotherapy outcomes in breast cancer.

Bhattarai, Shanta / Mackeyev, Yuri / Venkatesulu, Bhanu P / Krishnan, Sunil / Singh, Pankaj K

Nanoscale

2021 Volume 13, Issue 45, Page(s) 19056–19065

Abstract: CXC chemokine receptor 4 (CXCR4) is overexpressed on most breast cancer cell surfaces including triple negative breast cancer (TNBC) which lacks traditional receptor overexpression. We targeted gold nanoparticles (GNPs) to this ... ...

Abstract	CXC chemokine receptor 4 (CXCR4) is overexpressed on most breast cancer cell surfaces including triple negative breast cancer (TNBC) which lacks traditional receptor overexpression. We targeted gold nanoparticles (GNPs) to this receptor
MeSH term(s)	Animals ; Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Cell Line, Tumor ; Female ; Gold ; Humans ; Metal Nanoparticles ; Mice ; Receptors, CXCR4/genetics ; Triple Negative Breast Neoplasms/drug therapy ; Xenograft Model Antitumor Assays
Chemical Substances	CXCR4 protein, human ; Receptors, CXCR4 ; Gold (7440-57-5)
Language	English
Publishing date	2021-11-25
Publishing country	England
Document type	Journal Article
ZDB-ID	2515664-0
ISSN	2040-3372 ; 2040-3364
ISSN (online)	2040-3372
ISSN	2040-3364
DOI	10.1039/d1nr05385j
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Demography, patterns of care, and survival outcomes in patients with salivary duct carcinoma: an individual patient data analysis of 857 patients.

Giridhar, Prashanth / Venkatesulu, Bhanu Prasad / Yoo, Ryan / V, Pragathee / Rath, Goura K / Mallick, Supriya / Upadhyay, Ashishdutt / Chan, Dennis Pai

Future science OA

2022 Volume 8, Issue 4, Page(s) FSO791

Abstract: ... negativity significantly worse OS. Patients with surgery had a favorable median PFS (p = 0.000) and OS (p = 0 ... 077). Patients with adjuvant radiation had better PFS (30 vs 18 months; p = 0.077).: Conclusion ...

Abstract	Aim: Salivary duct carcinoma (SDC) is a rare and aggressive malignancy. The optimal treatment protocols are debated. Methodology: A systematic search and individual patient data analysis of published cases of SDC was performed. SPSS v21 was used for statistical analysis. Results: Data of 857 patients available. Median overall survival (OS) and progression-free survival (PFS) of the entire cohort 42 months and 24 months. Nodal involvement, males, primary size >5 cm, androgen receptor (AR) negativity significantly worse OS. Patients with surgery had a favorable median PFS (p = 0.000) and OS (p = 0.077). Patients with adjuvant radiation had better PFS (30 vs 18 months; p = 0.077). Conclusion: SDC has modest survival. Surgery and adjuvant radiation should be advocated for all patients. AR expression appears prognostic for survival.
Language	English
Publishing date	2022-03-08
Publishing country	England
Document type	Journal Article
ISSN	2056-5623
ISSN	2056-5623
DOI	10.2144/fsoa-2021-0052
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Local Therapy for Oligoprogressive Disease: A Systematic Review of Prospective Trials.

Kim, Hans / Venkatesulu, Bhanu P / McMillan, Matthew T / Verma, Vivek / Lin, Steven H / Chang, Joe Y / Welsh, James W

International journal of radiation oncology, biology, physics

2022 Volume 114, Issue 4, Page(s) 676–683

Abstract: Purpose: The successes of local therapy for oligometastatic cancers cannot be extrapolated to oligoprogressive disease (OPD) because they are distinct clinical entities. Given the limited prospective data on OPD to date, summative analyses are urgently ... ...

Abstract	Purpose: The successes of local therapy for oligometastatic cancers cannot be extrapolated to oligoprogressive disease (OPD) because they are distinct clinical entities. Given the limited prospective data on OPD to date, summative analyses are urgently needed. Methods and materials: Inclusion criteria for this Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-guided systematic review were as follows. First, only prospective data were included. Second, progression had to have occurred on active/ongoing systemic therapy. Third, the number of progressing areas of disease had to be explicitly listed and ≤5 in number. Fourth, all progressing sites had to undergo local therapy (radiation therapy [RT] /surgery/nonradiation ablative procedures). Results: Eight trials met criteria (summing 290 patients), the vast majority of which used stereotactic RT as the local modality (most commonly, 19-20 Gy in 1 fraction, 27-33 Gy in 3 fractions, or 35-50 Gy in 5 fractions). A study on non-small cell lung cancer (NSCLC) demonstrated that stereotactic RT improved progression-free survival (PFS) and overall survival compared with historical values with systemic therapy alone. Two additional studies on epidermal growth factor receptor mutated (EGFRm) NSCLC also showed acceptable PFS with local therapy, particularly in patients who oligoprogressed on osimertinib. The only randomized trial analyzed herein showed that local therapy improved PFS for NSCLC but not breast cancer. Two trials in castration-resistant prostate cancer illustrated that a substantial proportion of patients did not require any changes in hormonal therapy or delayed the need to change systemic therapies. Lastly, 2 trials of renal cell carcinoma showed high (90%-100%) local control and median PFS of 9 months, and potentially a prolonged time to change systemic therapy. Lastly, from all patients in all trials, local therapy was tolerated well, with only 7 instances of grade 3+ toxicities. Conclusions: Based on the limited data, local therapy for oligoprogression is safe and yields encouraging short-term preliminary outcomes, but trials with larger sample sizes and longer follow-up are required for more robust conclusions.
MeSH term(s)	ErbB Receptors ; Humans ; Neoplasms/therapy ; Prospective Studies ; Radiosurgery/methods
Chemical Substances	ErbB Receptors (EC 2.7.10.1)
Language	English
Publishing date	2022-08-13
Publishing country	United States
Document type	Journal Article ; Systematic Review ; Research Support, Non-U.S. Gov't
ZDB-ID	197614-x
ISSN	1879-355X ; 0360-3016
ISSN (online)	1879-355X
ISSN	0360-3016
DOI	10.1016/j.ijrobp.2022.08.027
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1218: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Bombarding Oligoprogression: Oncologic Outcomes After Radiation to Patients With Oligoprogressive Non-Small Cell Lung Cancer on Maintenance Systemic Therapy.

Chou, Brian / Lee, Jae Han / Saetern, Lonnie / Venkatesulu, Bhanu Prasad / Welsh, James S / Harkenrider, Matthew M

American journal of clinical oncology

2024 Volume 47, Issue 4, Page(s) 155–160

Abstract: ... to 18.2) compared with patients with a history of prior radiation at 4.1 months (IQR: 2.7 to 12; P = 0 ... months (IQR: 2.7 to 8.5; P = 0.018). Two patients (9%) had grade 3 chronic toxicity related to RT and ...

Abstract	Objectives: This study aims to evaluate the efficacy and toxicity of radiotherapy (RT) to oligoprogressive metastatic non-small cell lung cancer (NSCLC). Methods: This is a retrospective analysis of 23 patients with metastatic NSCLC on maintenance systemic therapy, developed oligoprogression (1 to 5 sites), and all oligoprogressive sites amenable to and treated with RT. The primary endpoints included progression-free survival (PFS) and median time to start next-line therapy (MTT). Kaplan-Meier survival analysis and log-rank testing were performed using R-Studio software. Results: Twenty-three patients met the inclusion criteria. The median overall survival for the entire cohort was 31.3 months (interquartile range [IQR]: 17.86 to 45.4). The median event-free survival for the entire cohort was 8.3 months (IQR: 2.7 to 12). Patients with no prior radiation had longer median event-free survival of 11.9 months (IQR: 8.4 to 18.2) compared with patients with a history of prior radiation at 4.1 months (IQR: 2.7 to 12; P = 0.041). The local control rate for the treated lesions was 97.5%. At 12 months follow-up, 6 (43%) of 14 living patients maintained systemic therapy without initiating next-line therapy. The median PFS for the entire cohort was 8.4 months (IQR: 4.1 to 17.5). Patients who did not receive prior radiation had longer median PFS of 11.9 months (IQR: 8.4 to 18.2) compared with patients who received prior radiation 6.2 months (IQR: 2.7 to 8.5; P = 0.018). Two patients (9%) had grade 3 chronic toxicity related to RT and were medically managed. Conclusion: We identified that in patients with oligoprogressive metastatic NSCLC, targeted RT to all progressive sites yielded high LC and favorable rates of PFS and MTT.
MeSH term(s)	Humans ; Carcinoma, Non-Small-Cell Lung/radiotherapy ; Lung Neoplasms/pathology ; Retrospective Studies ; Progression-Free Survival
Language	English
Publishing date	2024-01-09
Publishing country	United States
Document type	Journal Article
ZDB-ID	604536-4
ISSN	1537-453X ; 0277-3732
ISSN (online)	1537-453X
ISSN	0277-3732
DOI	10.1097/COC.0000000000001077
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1557: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Multi-institutional Development and Validation of Contouring Guidelines for Para-aortic Elective Nodal Irradiation in Prostate Cancer Based on Patterns of Involvement on Targeted Molecular Imaging Positron Emission Tomography/Computed Tomography.

Saripalli, Anjali L / Lee, Brian / Adams, William / Bhandare, Niranjan / Venkatesulu, Bhanu P / Yoo, Ryan K / Price, Jennifer / Harmon, Grant A / Block, Alec M / Friedman, Nicholas / Harkenrider, Matthew M / Major, Erica J / Small, William / Wagner, Robert H / Welsh, James S / Solanki, Abhishek A

International journal of radiation oncology, biology, physics

2023 Volume 117, Issue 3, Page(s) 630–640

Abstract: Purpose: Molecular imaging better identifies anatomic regions of metastatic spread of prostate cancer compared with conventional imaging, resulting in para-aortic (PA) nodal metastases being increasingly identified. Consequently, some radiation ... ...

Abstract	Purpose: Molecular imaging better identifies anatomic regions of metastatic spread of prostate cancer compared with conventional imaging, resulting in para-aortic (PA) nodal metastases being increasingly identified. Consequently, some radiation oncologists electively treat the PA lymph node region in patients with gross or high risk of PA nodal involvement. The anatomic locations of at-risk PA lymph nodes for prostate cancer are unknown. Our objective was to use molecular imaging to develop guidelines for the optimal delineation of the PA clinical target volume (CTV) in patients with prostate cancer. Methods and materials: We conducted a multi-institutional retrospective cohort study of patients with prostate cancer undergoing Results: Five hundred fifty-nine patients had molecular PET/CT imaging in the development data set (78% Conclusions: We used molecular PET/CT imaging to determine the anatomic locations of PA metastases to develop contouring guidelines for creating a prostate cancer PA CTV. Although the optimal patient selection and clinical benefits of PA radiation therapy remain uncertain, our results will aid in delineating the optimal target when PA radiation therapy is pursued.
MeSH term(s)	Male ; Humans ; Positron Emission Tomography Computed Tomography/methods ; Retrospective Studies ; Lymphatic Metastasis/diagnostic imaging ; Lymphatic Metastasis/radiotherapy ; Lymphatic Metastasis/pathology ; Lymph Nodes/diagnostic imaging ; Lymph Nodes/pathology ; Prostatic Neoplasms/diagnostic imaging ; Prostatic Neoplasms/radiotherapy ; Prostatic Neoplasms/pathology ; Molecular Imaging
Chemical Substances	fluciclovine F-18 (38R1Q0L1ZE)
Language	English
Publishing date	2023-05-16
Publishing country	United States
Document type	Journal Article
ZDB-ID	197614-x
ISSN	1879-355X ; 0360-3016
ISSN (online)	1879-355X
ISSN	0360-3016
DOI	10.1016/j.ijrobp.2023.05.017
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1218: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Risk of secondary malignant neoplasms in children following proton therapy vs. photon therapy for primary CNS tumors: A systematic review and meta-analysis.

Upadhyay, Rituraj / Yadav, Divya / Venkatesulu, Bhanu P / Singh, Raj / Baliga, Sujith / Raval, Raju R / Lazow, Margot A / Salloum, Ralph / Fouladi, Maryam / Mardis, Elaine R / Zaorsky, Nicholas G / Trifiletti, Daniel M / Paulino, Arnold C / Palmer, Joshua D

Frontiers in oncology

2022 Volume 12, Page(s) 893855

Abstract: Background: Central nervous system tumors are now the most common primary neoplasms seen in children, and radiation therapy is a key component in management. Secondary malignant neoplasms (SMNs) are rare, but dreaded complications. Proton beam therapy ( ... ...

Abstract	Background: Central nervous system tumors are now the most common primary neoplasms seen in children, and radiation therapy is a key component in management. Secondary malignant neoplasms (SMNs) are rare, but dreaded complications. Proton beam therapy (PBT) can potentially minimize the risk of SMNs compared to conventional photon radiation therapy (RT), and multiple recent studies with mature data have reported the risk of SMNs after PBT. We performed this systematic review and meta-analysis to characterize and compare the incidence of SMNs after proton and photon-based radiation for pediatric CNS tumors. Methods: A systematic search of literature on electronic (PubMed, Cochrane Central, and Embase) databases was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) method. We included studies reporting the incidence and nature of SMNs in pediatric patients with primary CNS tumors. The crude incidence of SMNs and all secondary neoplasms were separately extracted, and the random-effects model was used for pooled analysis and subgroup comparison was performed between studies using photons vs. protons. Results: Twenty-four studies were included for analysis. A total of 418 SMNs were seen in 38,163 patients. The most common SMN were gliomas (40.6%) followed by meningiomas (38.7%), sarcomas (4.8%), and thyroid cancers (4.2%). The median follow-up was 8.8 years [3.3-23.2].The median latency to SMN for photons and protons were 11.9 years [5-23] and 5.9 years [5-6.7], respectively. The pooled incidence of SMNs was 1.8% (95% CI: 1.1%-2.6%, I Conclusion: We observed similar rates of SMN with PBT at 1.5% compared to 1.8% with photon-based RT for pediatric CNS tumors. We observed a shorter latency to SMN with PBT compared to RT. With increasing use of pencil beam scanning PBT and VMAT, further studies are warranted to evaluate the risk of secondary cancers in patients treated with these newer modalities.
Language	English
Publishing date	2022-08-12
Publishing country	Switzerland
Document type	Systematic Review
ZDB-ID	2649216-7
ISSN	2234-943X
ISSN	2234-943X
DOI	10.3389/fonc.2022.893855
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Low-Dose Radiation Therapy for COVID-19: Promises and Pitfalls.

Venkatesulu, Bhanu P / Lester, Scott / Hsieh, Cheng-En / Verma, Vivek / Sharon, Elad / Ahmed, Mansoor / Krishnan, Sunil

JNCI cancer spectrum

2020 Volume 5, Issue 1, Page(s) pkaa103

Abstract: The coronavirus disease-2019 (COVID-19) pandemic caused by SARS-CoV-2 has exacted an enormous toll on healthcare systems worldwide. The cytokine storm that follows pulmonary infection is causally linked to respiratory compromise and mortality in the ... ...

Abstract	The coronavirus disease-2019 (COVID-19) pandemic caused by SARS-CoV-2 has exacted an enormous toll on healthcare systems worldwide. The cytokine storm that follows pulmonary infection is causally linked to respiratory compromise and mortality in the majority of patients. The sparsity of viable treatment options for this viral infection and the sequelae of pulmonary complications have fueled the quest for new therapeutic considerations. One such option, the long-forgotten idea of using low-dose radiation therapy, has recently found renewed interest in many academic centers. We outline the scientific and logistical rationale for consideration of this option and the mechanistic underpinnings of any potential therapeutic value, particularly as viewed from an immunological perspective. We also discuss the preliminary and/or published results of prospective trials examining low-dose radiation therapy for COVID-19.
MeSH term(s)	COVID-19/epidemiology ; COVID-19/radiotherapy ; COVID-19/virology ; Cytokines/metabolism ; Dose-Response Relationship, Radiation ; Host-Pathogen Interactions/radiation effects ; Humans ; Leukocytes, Mononuclear/metabolism ; Leukocytes, Mononuclear/radiation effects ; Leukocytes, Mononuclear/virology ; Pandemics ; Radiation Dosage ; Radiotherapy Dosage ; SARS-CoV-2/physiology ; SARS-CoV-2/radiation effects ; Virus Internalization/radiation effects ; Virus Replication/radiation effects
Chemical Substances	Cytokines
Language	English
Publishing date	2020-11-19
Publishing country	England
Document type	Journal Article ; Review
ISSN	2515-5091
ISSN (online)	2515-5091
DOI	10.1093/jncics/pkaa103
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED